Loading patent…
AssigneeMedarex, Inc.
InventorsAlison J. Witte, Denise Williams, Josephine M. Cardarelli, David J. King, David B. Passmore
Estimating the term…
The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.
A method of inhibiting the biological activity of interferon alpha comprising contacting interferon alpha with an effective amount of an isolated anti-interferon alpha monoclonal antibody, or an antigen binding portion thereof, which binds an epitope on a human interferon alpha polypeptide recognized by an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
A method of inhibiting the biological activity of interferon alpha comprising contacting interferon alpha with an effective amount of an isolated anti-interferon alpha monoclonal antibody, or antigen binding portion thereof comprising:
A method of inhibiting the biological activity of interferon alpha comprising contacting interferon alpha with an effective amount of an isolated anti-interferon alpha monoclonal antibody, or antigen binding portion thereof, which comprises:
Dependencies are inferred from the claim text.